Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI-Powered test aims to predict best cancer treatment for each patient

NCT ID NCT06929338

Diagnosis Sponsor: First Ascent Biomedical Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Sep 03, 2026 · Updated 2 times

Summary

This study tests a new platform called xDRIVE that combines drug sensitivity testing and AI to predict which treatments will work best for people with advanced colorectal cancer. The platform will not provide treatment itself but will give doctors a recommendation. The goal is to see if xDRIVE can accurately predict treatment response in at least 80% of the 30 participants. If it works, this could help personalize cancer therapy and avoid ineffective treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
xDRIVE functional precision medicine platform (diagnostic test)
What this could lead to
If successful, this platform could help doctors choose the most effective therapy for each patient, improving outcomes and avoiding ineffective treatments.
What could go wrong
This is a small, early feasibility study with only 30 participants. The platform may not reach the target accuracy, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Expected to start

Sep 2025

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants with mCRC who need clinical tumor biopsy or resection and need to start systemic therapy for measurable disease.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants (men and women) enrolled in internal review board (IRB) 622-00 and meet the following criteria. * Participants ≥18 years of age with a diagnosis of mCRC who are willing to consent to the study * Participants with Eastern Cooperative Group (ECOG) performance status of 0, 1, or 2. * Participants with measurable disease * Participants who need to start SOC cancer-directed systemic therapy * Participants able to provide treatment and outcome information from previous lines of therapy. * Participants who will need a tumor biopsy, excision, or resection as part of their routine clinical care. * Participants willing to have a blood draw performed for matched normal material. * Participants who plan to have their first radiographic assessment of their cancer at Mayo Clinic. Exclusion Criteria: * Participants who do not have malignant tissue available or safely accessible or do not have sufficient amount of tissue from anticipated biopsy, excision or resection for testing. * Participants who do not have measurable disease. * Participants with insufficient health indicators to undergo therapeutic intervention for mCRC based on treating oncologist's clinical assessment. * Participants with other concurrent cancers besides mCRC which also require ongoing cancer-directed therapy. * Participants who cannot provide an informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic colon adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colon adenocarcinoma colonic neoplasm colorectal cancer colorectal neoplasm malignant colon neoplasm metastatic malignant neoplasm in the colon rectal cancer rectal carcinoma rectal neoplasm rectum adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic colon adenocarcinoma Metastatic colon cancer Metastatic rectal adenocarcinoma Metastatic rectal carcinoma Metastatic rectum cancer

More trials for these conditions

Other studies related to the condition(s) this trial covers.